5,139 results match your criteria braf v600e

A circulating subset of BRAF -positive cells in infants with high-risk Langerhans cell histiocytosis treated with BRAF inhibitors.

Br J Haematol 2021 Jul 26. Epub 2021 Jul 26.

INSERM, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Paris, France.

BRAF inhibitors are an effective treatment for BRAF -mutated, risk-organ-positive Langerhans cell histiocytosis (RO LCH). However, cell-free BRAF DNA often persists during therapy and recurrence frequently occurs after therapy discontinuation. To identify a pathological reservoir of BRAF -mutated cells, we studied peripheral blood cells obtained from six infants with RO multisystem (MS) LCH that received targeted therapy. Read More

View Article and Full-Text PDF

Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer.

Biomed Res Int 2021 1;2021:9937742. Epub 2021 Jul 1.

Department of Ultrasound Medicine, Gansu Provincial Hospital, Lanzhou 730000, China.

The aim of this study was to explore the correlation between ultrasound-guided fine-needle aspiration cytology(US-FNAC) combined with BRAF V600E mutation analysis and central neck lymph node metastasis in cN0 papillary thyroid cancer, so as to provide reliable molecular evidence to use it for preoperative evaluation, operation procedure design, and postoperative follow-up planning in clinic. Specimens were obtained from 250 patients with cN0 thyroid cancer (TI-RADS≥4a, highly suspected of PTC by US-FNAC) after bilateral thyroidectomy and central neck lymph node dissection with accessible postoperative pathologic results of PTC and central neck lymph nodes and used for cytological diagnosis by H&E stain and BRAF V600E mutation detection. Single-factor analysis showed that differences between the central neck lymph node metastasis and nonmetastasis groups were statistically significant in gender, BRAF V600E mutation, and extracapsular extension. Read More

View Article and Full-Text PDF

Concomitant Langerhans cell histiocytosis of cervical lymph nodes in adult patients with papillary thyroid carcinoma: A report of two cases and review of the literature.

Autops Case Rep 2021 12;11:e2021253. Epub 2021 Mar 12.

King Hussein Cancer Center, Department of Pathology and Laboratory Medicine, Amman, Jordan.

Objective: : Langerhans cell histiocytosis (LCH) is an uncommon entity of unknown etiology. It contains a wide range of clinical presentations. The discovery of oncogenic mutation in LCH has provided additional evidence that LCH is a neoplasm. Read More

View Article and Full-Text PDF

Serum TSH levels are associated with postoperative recurrence and lymph node metastasis of papillary thyroid carcinoma.

Am J Transl Res 2021 15;13(6):6108-6116. Epub 2021 Jun 15.

Department of Breast Surgery, The Second Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang, PR China.

Objective: To explore the relationship between thyroid-stimulating hormone (TSH) levels in the serum and postoperative recurrence and lymph node metastasis (LNM) in papillary thyroid cancer (PTC) patients after surgery.

Methods: We selected 272 patients diagnosed with PTC from June 2011 to July 2014. The clinical and pathological data of 272 PTC patients were collected at the First Affiliated Hospital of Wenzhou Medical University and analysed retrospectively. Read More

View Article and Full-Text PDF

Lenvatinib targets PDGFR-β pericytes and inhibits synergy with thyroid carcinoma cells: novel translational insights.

J Clin Endocrinol Metab 2021 Jul 24. Epub 2021 Jul 24.

Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Experimental Pathology, Cancer Research Institute (CRI), Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Context: Pericyte populations abundantly express tyrosine-kinases (TK, e.g. PDGFR-β) and impact therapeutic response. Read More

View Article and Full-Text PDF

Prognostic Factors for Survival in Transverse Colon Cancers.

J Gastrointest Cancer 2021 Jul 24. Epub 2021 Jul 24.

Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne, Turkey.

Background: Transverse colon cancer (TCC) is a rare condition that accounts for 10% of all colon cancers. TCC was accepted more likely right-sided colon cancers. We aimed to investigate whether TCC differs from other colon tumors by using clinical, pathological, and molecular prognostic factors known to be important in colon cancer and if it differs in its own anatomical structure. Read More

View Article and Full-Text PDF

Autophagy Inhibition in BRAF-Driven Cancers.

Cancers (Basel) 2021 Jul 13;13(14). Epub 2021 Jul 13.

Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.

Several BRAF-driven cancers, including advanced BRAF-driven melanoma, non-small-cell lung carcinoma, and thyroid cancer, are currently treated using first-line inhibitor combinations of BRAF plus MEK1/2. However, despite the success of this vertical inhibition strategy, the durability of patient response is often limited by the phenomenon of primary or acquired drug resistance. It has recently been shown that autophagy, a conserved cellular recycling process, is increased in BRAF-driven melanoma upon inhibition of BRAF signaling. Read More

View Article and Full-Text PDF

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer.

Cancers (Basel) 2021 Jul 12;13(14). Epub 2021 Jul 12.

Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City 23652, Taiwan.

Differentiated thyroid cancer (DTC) patients are usually known for their excellent prognoses. However, some patients with DTC develop refractory disease and require novel therapies with different therapeutic mechanisms. Targeting Wee1 with adavosertib has emerged as a novel strategy for cancer therapy. Read More

View Article and Full-Text PDF

Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAF mutant glioma.

Mol Cell Proteomics 2021 Jul 20:100123. Epub 2021 Jul 20.

The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Division of Pediatric Oncology, Baltimore, MD; The Johns Hopkins University School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, MD.

The mitogen-activated protein kinase (MAPK) pathway is one of the most frequently altered pathways in cancer. It is involved in the control of cell proliferation, invasion, and metabolism, and can cause resistance to therapy. A number of aggressive malignancies including melanoma, colon cancer, and glioma, are driven by a constitutively activating missense mutation (V600E) in the BRAF component of the pathway. Read More

View Article and Full-Text PDF

Yes-activated protein promotes primary resistance of V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors.

J Gastrointest Oncol 2021 Jun;12(3):953-963

Medical Oncology Department of Gastrointestinal Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.

Background: Most colorectal cancer (CRC) patients with the V600E mutation display resistance to chemotherapy and targeted medicinal treatments. Thus, exploring new drugs and drug resistance mechanisms for the V600E mutation has become an urgent clinical priority.

Methods: MTS experiment, cell cloning experiment, cell scratching experiment, Transwell experiment, chromatin immunoprecipitation (ChIP), quantitative polymerase chain reaction (qPCR) and flow cytometry are used. Read More

View Article and Full-Text PDF

Less-invasive diagnosis of disseminated epithelioid glioblastoma harboring V600E mutation by cerebrospinal fluid analysis-A case report.

Clin Case Rep 2021 Jul 16;9(7):e04551. Epub 2021 Jul 16.

Department of Neurosurgery Brain Research Institute Niigata University Niigata Japan.

Spinal dissemination in epithelioid glioblastoma can be diagnosed by cerebrospinal fluid cytology and liquid biopsy to detect V600E mutation. Read More

View Article and Full-Text PDF

Ocular Juvenile Xanthogranuloma With BRAF V600E Mutation in a Child.

J Pediatr Ophthalmol Strabismus 2021 Jul-Aug;58(4):e19-e21. Epub 2021 Jul 1.

The authors present a case of bilateral painless progressive proptosis. A diagnosis of ocular juvenile xanthogranuloma was made based on clinical manifestations, histopathology, and immunohistochemistrical staining. Genetic testing discovered the BRAF V600E mutation. Read More

View Article and Full-Text PDF

Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal Malignancies.

Oncology (Williston Park) 2021 Jul 17;35(7):382-389. Epub 2021 Jul 17.

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. Because of the low incidence of target gene alterations such as HER2 or BRAF V600E in gastrointestinal cancers, very large screening platforms are needed to develop genome-based clinical trials. For those reasons, ctDNA-based screening studies are being actively conducted; among them are the GOZILA (Guardant Originates in Zipangu Liquid biopsy Arrival) study in Japan and the COLOMATE (COlorectal Cancer Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy) study in the United States. Read More

View Article and Full-Text PDF

Central diabetes insipidus developing in a 6-year-old patient 4 years after the remission of unifocal bone Langerhans cell histiocytosis.

Clin Pediatr Endocrinol 2021 10;30(3):149-153. Epub 2021 Jul 10.

Department of Pediatrics, Musashino Red Cross Hospital, Tokyo, Japan.

A six-year-old boy was referred with a one-and-a-half months history of polyuria and polydipsia. At the age of two, he had a single lytic bone lesion in his femoral head, diagnosed as Langerhans cell histiocytosis (LCH) by biopsy at another hospital. As no other affected organs were detected and the affected bone lesion was self-limited, he was not followed up afterward and was doing well. Read More

View Article and Full-Text PDF

Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus.

Cancers (Basel) 2021 Jul 5;13(13). Epub 2021 Jul 5.

Department of Radiation Molecular Epidemiology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.

Childhood papillary thyroid carcinoma (PTC) diagnosed after the Chernobyl accident in Belarus displayed a high frequency of gene rearrangements and low frequency of point mutations. Since 2001, only sporadic thyroid cancer occurs in children aged up to 14 years but its molecular characteristics have not been reported. Here, we determine the major oncogenic events in PTC from non-exposed Belarusian children and assess their clinicopathological correlations. Read More

View Article and Full-Text PDF

Clinical Impact of Primary Tumor Location and V600E, and Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer.

Anticancer Res 2021 Aug;41(8):3905-3915

Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Background/aim: Primary tumor location and RAS and BRAF V600E mutations are predictors of the efficacy of epidermal growth factor receptor (EGFR) inhibitors. However, there are limited reports on their effects on the outcomes of third-line chemotherapy with EGFR inhibitors in metastatic colorectal cancer (mCRC) patients.

Patients And Methods: We retrospectively collected the clinical data of KRAS exon 2 wild type (WT) mCRC patients treated with EGFR inhibitor monotherapy or EGFR inhibitor plus irinotecan as third-line chemotherapy. Read More

View Article and Full-Text PDF

Thymic Adenocarcinoma with Positivity for Thyroid Transcription Factor-1 and a BRAF V600E Mutation: A Case Report.

Intern Med 2021 Jul 17. Epub 2021 Jul 17.

Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan.

Thymic adenocarcinomas are rare. We herein report for the first time a case of thymic adenocarcinoma with positivity for thyroid transcription factor-1 (TTF-1) and a BRAF V600E mutation. A 50-year-old woman had persistent suffocation and chest pain. Read More

View Article and Full-Text PDF

Nomograms to predict ipsilateral and contralateral central lymph node metastasis in clinically lymph node-negative patients with solitary isthmic classic papillary thyroid carcinoma.

Surgery 2021 Jul 15. Epub 2021 Jul 15.

Department of Thyroid Surgery, The Third Affiliated Hospital of Soochow University, Changzhou First People's Hospital, Changzhou, Jiangsu, China. Electronic address:

Background: Isthmus-originating papillary thyroid carcinoma has unique clinicopathological characteristics. There are no specific guidelines regarding the extent of surgery for isthmic papillary thyroid carcinoma. We aimed to evaluate the characteristics of clinically lymph node-negative patients with solitary isthmic papillary thyroid carcinoma and to determine the best surgical protocol for these patients. Read More

View Article and Full-Text PDF

BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.

J Clin Endocrinol Metab 2021 Jul 17. Epub 2021 Jul 17.

Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.

Context: How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined.

Objective: To study whether BRAF V600E affected LNM-associated mortality in PTC.

Design, Setting, Participants: We retrospectively analyzed the effect of LNM on PTC-specific mortality with respect to BRAF status in 2638 patients (2015 females and 623 males) from 11 centers in 6 countries, with median age of 46 (IQR 35-58) years and median follow-up time of 58 (IQR 26-107) months. Read More

View Article and Full-Text PDF

Intratumor morphologic and transcriptomic heterogeneity in BRAF-mutated metastatic colorectal adenocarcinomas.

ESMO Open 2021 Jul 13;6(4):100211. Epub 2021 Jul 13.

Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address:

Background: Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity provides the fuel for drug resistance; therefore, an accurate assessment of tumor heterogeneity is essential for the development of effective therapies. The purpose of this study was to dissect morphologic and molecular ITH in colorectal adenocarcinoma. Read More

View Article and Full-Text PDF

Comparative study of BRAF gene mutations in ovarian serous tumors by immunohistochemistry and DNA sequencing.

J BUON 2021 May-Jun;26(3):670-676

Department of Pathology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 200040, P.R. China.

Purpose: Somatic mutations in the BRAF gene are common in several types of cancer, especially in ovarian serous cancer (OSC). Normally, the BRAF protein is switched on and off in response to signals that control cell growth and development.

Methods: To investigate the correlation between the mutation of BRAF gene and the expression of BRAF protein in OSC, pyrosequencing was performed to detect the mutation of the 600th codon in BRAF gene (written as Val600Glu or V600E) in 23 cases of high-grade serous ovarian cancer (HGSC), 28 cases of low-grade serous ovarian cancer (LGSC) and 72 cases of serous borderline ovarian tumors (SBT). Read More

View Article and Full-Text PDF

Diagnostic value of puncture feeling combined with BRAF V600E mutation in repeat US-FNA biopsy of Bethesda III thyroid nodules.

Gland Surg 2021 Jun;10(6):2019-2027

School of Graduate, Hebei Medical University, Shijiazhuang, China.

Background: The diagnosis and treatment of Bethesda III thyroid nodules has always been controversial. Our aim is to study the value of puncture feeling combined with BRAF V600E mutation detection in the diagnosis of Bethesda III thyroid nodules in repeat fine needle aspiration (FNA).

Methods: From January 1, 2017 to December 31, 2021, a total of 1,114 thyroid nodules were included, of which Bethesda III thyroid nodules accounted for 12. Read More

View Article and Full-Text PDF

[Therapeutic Strategy for BRAF-Mutated Cancer].

Gan To Kagaku Ryoho 2021 Jul;48(7):861-865

Dept. of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University.

BRAF mutation is occurred in about 8% of human malignancy, including 40-60% in malignant melanoma, 50% in thyroid papillary cancer, 10% in colorectal cancer, and a few percent of non-small cell lung cancer. Activated mutation of BRAF is mainly p. V600E mutation. Read More

View Article and Full-Text PDF

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.

Pathologe 2021 Jul 14. Epub 2021 Jul 14.

Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany.

In the past 25 years, treatment of metastatic colorectal cancer (mCRC) has undergone profound changes. The approval of newer chemotherapeutics such as irinotecan and oxaliplatin was followed in 2005 by the first targeted therapies, for example, monoclonal antibodies directed against the epidermal growth factor receptor (EGFR), as cetuximab and panitumumab, or the angiogenesis inhibitors bevacizumab, ramucirumab, and aflibercept. With the rapidly progressing molecular characterization of mCRC in the last 10 years and the classification of the disease in four consensus subtypes, further changes are emerging, which will promote, among other things, the introduction of protein-kinase inhibitors developed for specific molecular aberrations as well as immune checkpoint inhibitors into the treatment algorithm. Read More

View Article and Full-Text PDF

Predicting factors of central lymph node metastasis and BRAF mutation in Chinese population with papillary thyroid carcinoma.

World J Surg Oncol 2021 Jul 13;19(1):211. Epub 2021 Jul 13.

Department of Pathology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, 7# Weiwu Road, Zhengzhou, 450003, Henan Province, China.

Objective: The aim of this study was to evaluate the predictive factors of central lymph node metastasis (CLNM) and BRAF mutation in Chinese patients with papillary thyroid carcinoma (PTC).

Methods: A total of 943 PTC patients who underwent thyroidectomy from 2014 to 2016 at our hospital were enrolled. Those patients were divided into PTC > 10 mm and papillary thyroid microcarcinoma (PTMC) groups by tumor size. Read More

View Article and Full-Text PDF

Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAF melanoma-bearing mice.

Int J Pharm 2021 Jul 9:120876. Epub 2021 Jul 9.

Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Electronic address:

Melanoma, the most malignant form of skin cancer, shows resistance to traditional anticancer drugs including paclitaxel (PTX). Furthermore, over 50% of melanoma cases express the BRAF mutation which activates the MAPK pathway increasing cell proliferation and survival. In the current study, we investigated the capacity of the combination therapy of PTX and the MAPK inhibitor, PD98059, to enhance the cytotoxicity of PTX against melanoma and therefore improve treatment outcomes. Read More

View Article and Full-Text PDF

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer.

Front Oncol 2021 23;11:601722. Epub 2021 Jun 23.

Department of Oncology, Infermi's Hospital, Azienda Unità Sanitaria Locale (AUSL) della Romagna, Faenza, Italy.

Around 8-12% of patients with advanced colon rectal cancer (CRC) present with BRAF alterations, in particular V600E mutation, which is associated with right-side, poorly differentiated and mucinous type tumors. The presence of BRAF mutation (BRAF-mt) has been identified as a hallmark of poor prognosis and treatment optimization in this patient subgroup is an important goal. Currently, the standard of care is an aggressive strategy involving triplet chemotherapy and anti-VEGF agents, but new therapeutic approaches are emerging. Read More

View Article and Full-Text PDF

Plasma proteome alterations by MAPK inhibitors in BRAF-mutated metastatic cutaneous melanoma.

Neoplasia 2021 Aug 8;23(8):783-791. Epub 2021 Jul 8.

Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.

Approximately half of metastatic cutaneous melanomas (CM) harbor a mutation in the BRAF protooncogene, upregulating the mitogen-activated protein kinase (MAPK)-pathway. The development of inhibitors targeting the MAPK pathway (MAPKi), i.e. Read More

View Article and Full-Text PDF

Pulmonary sclerosing pneumocytoma masquerading adenocarcinoma with co-existing BRAF V600E and PTEN mutation.

Cancer Treat Res Commun 2021 Jun 29;28:100429. Epub 2021 Jun 29.

Department of Nuclear Medicine, All India Institute of Medical Sciences, Raipur, India.

We report a case of a massive primary sclerosing pneumocytoma (PSP) involving the right lower lobe adhering esophagus with small synchronous PSP on the superior segment of the left lower lobe with concurrent mutation for B-RAF proto-oncogene, serine/threonine kinase (BRAF V600E), and phosphatase and tensin homolog (PTEN) gene in a young female. She underwent right lower lobectomy and mediastinal lymph node dissection under single lung ventilation with tumor-free margins on diagnosis-based findings of preoperative computed tomography-guided biopsy and positron emission tomography. Histopathology was suggestive of PSP-papillary variant with concurrent mutation of BRAF V600E and PTEN genes. Read More

View Article and Full-Text PDF